title: Patient perspectives on choosing buprenorphine over methadone in an urban, equal-access system.
abstract: BACKGROUND
  Recent policy initiatives in Baltimore City, MD significantly reduced access disparities between methadone and buprenorphine in the publicly funded treatment sector.
  
  
  OBJECTIVE
  This study examines reasons for choosing buprenorphine over methadone among patients with access to both medications.
  
  
  METHODS
  This study was embedded within a larger clinical trial conducted at two outpatient substance abuse treatment programs offering buprenorphine. Qualitative and quantitative data on treatment choice were collected for new patients starting buprenorphine treatment (n = 80). The sample consisted of predominantly urban African American (94%) heroin users who had prior experience with non-prescribed street buprenorphine (85%), and opioid agonist treatment (68%). Qualitative data were transcribed and coded for themes, while quantitative data were analyzed using descriptive and bivariate statistics.
  
  
  RESULTS
  Participants typically conveyed their choice of buprenorphine treatment as a decision against methadone. Buprenorphine was perceived as a helpful medication while methadone was perceived as a harmful narcotic with multiple unwanted physical effects. Positive experiences with non-prescribed "street buprenorphine" were a central factor in participants' decisions to seek buprenorphine treatment.
  
  
  CONCLUSIONS
  Differences in service structure between methadone and buprenorphine did not strongly influence treatment-seeking decisions in this sample. Personal experiences with medications and the street narrative surrounding them play an important role in treatment selection decisions.
  
  
  CONCLUSIONS
  This study characterizes important decision factors that underlie patients' selection of buprenorphine over methadone treatment.
authors.affiliation: Friends Research Institute, 1040 Park Avenue, Baltimore, MD 21201, USA. jgryczynski@friendsresearch.org
authors.forename: Jan
authors.initials: J
authors.lastname: Gryczynski
authors.forename: Jerome H
authors.initials: JH
authors.lastname: Jaffe
authors.forename: Robert P
authors.initials: RP
authors.lastname: Schwartz
authors.forename: Kristi A
authors.initials: KA
authors.lastname: Dušek
authors.forename: Nishan
authors.initials: N
authors.lastname: Gugsa
authors.forename: Cristin L
authors.initials: CL
authors.lastname: Monroe
authors.forename: Kevin E
authors.initials: KE
authors.lastname: O'Grady
authors.forename: Yngvild K
authors.initials: YK
authors.lastname: Olsen
authors.forename: Shannon Gwin
authors.initials: SG
authors.lastname: Mitchell
mesh_terms: D000328:Adult; D001741:Black or African American; D015142:Baltimore; D002047:Buprenorphine / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D013287:Illicit Drugs; D008297:Male; D008691:Methadone / Q000627:therapeutic use*; D008875:Middle Aged; D058850:Opiate Substitution Treatment / Q000379:methods* / Q000523:psychology; D009293:Opioid-Related Disorders / Q000188:drug therapy* / Q000534:rehabilitation; D057240:Patient Preference; D063487:Prescription Drug Misuse; D036301:Qualitative Research; D016320:Substance Abuse Treatment Centers; D014505:Urban Population
chemical_list: D013287:Illicit Drugs; D002047:Buprenorphine; D008691:Methadone